After a bit of a bumpy ride in 2019, Biogen’s injectable treatment for early Alzheimer’s is set for a late-stage clinical trial.
The Food and Drug Administration recently greenlit this latest trial of aducanumab, in which past study participants will be re-dosed with the drug, according to NeurologyLive.
Biogen halted four studies of aducanumab in March 2019 due to poor results, but a subsequent data analysis showed success with higher doses. Following this turn of events, the company in October announced that it would seek regulatory approval of the drug, McKnight’s reported at the time.
Past participants are now being recruited for the new trial. The first patients will likely be re-dosed starting in March 2020, according to Biogen’s website.
